Trial: 202106003

Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy And Safety Of Mosunetuzumab In Combination With Lenalidomide In Comparison To Rituximab In Combination With Lenalidomide In Patients With Follicular Lymphoma After At Least One Line Of Systemic Therapy

Phase

III (Cancer Control)

Principal Investigator

Bartlett, Nancy

Disease Site

Non-Hodgkin Lymphoma

Learn more about this study at: clinicaltrials.gov